Adding psychotherapy to antidepressant medication in depression and anxiety disorders: a meta-analysis
- PMID: 24497254
- PMCID: PMC3918025
- DOI: 10.1002/wps.20089
Adding psychotherapy to antidepressant medication in depression and anxiety disorders: a meta-analysis
Abstract
We conducted a meta-analysis of randomized trials in which the effects of treatment with antidepressant medication were compared to the effects of combined pharmacotherapy and psychotherapy in adults with a diagnosed depressive or anxiety disorder. A total of 52 studies (with 3,623 patients) met inclusion criteria, 32 on depressive disorders and 21 on anxiety disorders (one on both depressive and anxiety disorders). The overall difference between pharmacotherapy and combined treatment was Hedges' g = 0.43 (95% CI: 0.31-0.56), indicating a moderately large effect and clinically meaningful difference in favor of combined treatment, which corresponds to a number needed to treat (NNT) of 4.20. There was sufficient evidence that combined treatment is superior for major depression, panic disorder, and obsessive-compulsive disorder (OCD). The effects of combined treatment compared with placebo only were about twice as large as those of pharmacotherapy compared with placebo only, underscoring the clinical advantage of combined treatment. The results also suggest that the effects of pharmacotherapy and those of psychotherapy are largely independent from each other, with both contributing about equally to the effects of combined treatment. We conclude that combined treatment appears to be more effective than treatment with antidepressant medication alone in major depression, panic disorder, and OCD. These effects remain strong and significant up to two years after treatment. Monotherapy with psychotropic medication may not constitute optimal care for common mental disorders.
Keywords: Combined treatment; antidepressant medication; anxiety disorders; depressive disorders; dysthymia; meta-analysis; obsessive-compulsive disorder; psychotherapy.
Copyright © 2014 World Psychiatric Association.
Figures


Similar articles
-
The efficacy of psychotherapy and pharmacotherapy in treating depressive and anxiety disorders: a meta-analysis of direct comparisons.World Psychiatry. 2013 Jun;12(2):137-48. doi: 10.1002/wps.20038. World Psychiatry. 2013. PMID: 23737423 Free PMC article.
-
Obsessive-compulsive disorder has a reduced placebo (and antidepressant) response compared to other anxiety disorders: A meta-analysis.J Affect Disord. 2017 Aug 15;218:217-226. doi: 10.1016/j.jad.2017.04.068. Epub 2017 Apr 29. J Affect Disord. 2017. PMID: 28477500 Review.
-
Relative effects of CBT and pharmacotherapy in depression versus anxiety: is medication somewhat better for depression, and CBT somewhat better for anxiety?Depress Anxiety. 2011 Jul;28(7):560-7. doi: 10.1002/da.20829. Epub 2011 May 23. Depress Anxiety. 2011. PMID: 21608087
-
Initial severity and antidepressant efficacy for anxiety disorders, obsessive-compulsive disorder, and posttraumatic stress disorder: An individual patient data meta-analysis.Depress Anxiety. 2018 Jun;35(6):515-522. doi: 10.1002/da.22737. Epub 2018 Apr 16. Depress Anxiety. 2018. PMID: 29659102 Free PMC article.
-
Long-term Outcomes of Cognitive Behavioral Therapy for Anxiety-Related Disorders: A Systematic Review and Meta-analysis.JAMA Psychiatry. 2020 Mar 1;77(3):265-273. doi: 10.1001/jamapsychiatry.2019.3986. JAMA Psychiatry. 2020. PMID: 31758858 Free PMC article.
Cited by
-
Diagnosis and treatment of depression and cognitive impairment in late life.Ann N Y Acad Sci. 2015 May;1345(1):36-46. doi: 10.1111/nyas.12669. Epub 2015 Feb 5. Ann N Y Acad Sci. 2015. PMID: 25655026 Free PMC article. Review.
-
Cognitive-Behavioral Therapy for Anxiety in Parkinson's Disease.Behav Modif. 2020 Jul;44(4):552-579. doi: 10.1177/0145445519838828. Epub 2019 Mar 31. Behav Modif. 2020. PMID: 30931594 Free PMC article. Clinical Trial.
-
The Appalachia Mind Health Initiative (AMHI): a pragmatic randomized clinical trial of adjunctive internet-based cognitive behavior therapy for treating major depressive disorder among primary care patients.Trials. 2022 Jun 20;23(1):520. doi: 10.1186/s13063-022-06438-y. Trials. 2022. PMID: 35725644 Free PMC article. Clinical Trial.
-
Somatic Symptoms and Sleep Disorders: A Literature Review of Their Relationship, Comorbidities and Treatment.Healthcare (Basel). 2021 Aug 30;9(9):1128. doi: 10.3390/healthcare9091128. Healthcare (Basel). 2021. PMID: 34574901 Free PMC article. Review.
-
Standardization of health outcomes assessment for depression and anxiety: recommendations from the ICHOM Depression and Anxiety Working Group.Qual Life Res. 2017 Dec;26(12):3211-3225. doi: 10.1007/s11136-017-1659-5. Epub 2017 Aug 7. Qual Life Res. 2017. PMID: 28786017 Free PMC article.
References
-
- Kessler RC, Berglund P, Demler O, et al. National Comorbidity Survey Replication. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R) JAMA. 2003;289:3095–105. - PubMed
-
- Kessler RC, Berglund P, Demler O, et al. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005;62:593–602. - PubMed
-
- Ustun TB, Ayuso-Mateos JL, Chatterji S, et al. Global burden of depressive disorders in the year 2000. Br J Psychiatry. 2004;184:386–92. - PubMed
-
- Saarni SI, Suvisaari J, Sintonen H, et al. Impact of psychiatric disorders on health-related quality of life: general population survey. Br J Psychiatry. 2007;190:326–32. - PubMed
-
- Berto P, D'Ilario D, Ruffo P, et al. Depression: cost-of-illness studies in the international literature: a review. J Ment Health Policy Econ. 2000;3:3–10. - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous